Retroviral and transposon-based tet-regulated all-in-one vectors with reduced background expression and improved dynamic range
HUMAN GENE THERAPY 22:166–176 (February 2011)ª Mary Ann Liebert, Inc.
DOI: 10.1089/hum.2010.099
Retroviral and Transposon-Based Tet-Regulated
All-In-One Vectors with Reduced Background
Expression and Improved Dynamic Range
Niels Heinz,1 Axel Schambach,1 Melanie Galla,1 Tobias Maetzig,1 Christopher Baum,1
Rainer Loew,2 and Bernhard Schiedlmeier1
The regulated expression of therapeutic genes may become crucial in gene therapy when their constitutiveexpression interferes with cell fate in vivo. The efficient regulation of transgene expression requires tightly con-trolled inducible promoters, as shown for the tetracycline regulatory system (tet-system). However, its applicationrequires the introduction of two components into the target cell genome: the tet-responsive transactivator and theregulated expression cassette. In order to facilitate the usage of the tet-system for approaches in gene therapy, bothcomponents have to be transferred by a single vector, thus eliminating the preselection of transactivator positivecells. Published ‘‘all-in-one'' vectors for regulated transgene expression display a relatively low signal-to-noiseratio, resulting in regulatory windows of around 500-fold even in selected clones. In this study, we show that amodified vector architecture combined with the introduction of new tet-responsive promoters, Ptet, improved thedynamic range of such all-in-one vectors to levels up to 14,000-fold for viral and 25,000-fold for nonviral transfervectors in nonclonal human cell lines, and up to 2,800-fold in murine hematopoietic cell lines. This improvedregulation was the result of a strong reduction of background expression in the off-state, even if cells weretransduced at high multiplicity of infection, while induction remained at high levels. In addition, the resultsindicated that successful regulation of gene expression in different target cells depended on vector architecture aswell as the choice of the Ptet-promoter.
In the past, diverse modifications were introduced to
improve the tet-regulated transgene expression system.
Drug-inducible controlofgeneexpression isawidely These modifications have included improvements of the tet-
used strategy for investigation of gene function in many
responsive promoter, where a reduction of the tet-operator
basic areas of genetic and cellular biology. Regulated trans-
sequences (tetO) toward 36-nucleotide (nt) spacing from core
gene expression is also a desired safety feature in gene ther-
to core improved the regulatory behavior (Agha-Mohammadi
apy applications, allowing tightly controlled reversible gene
et al., 2004). The transactivator has also been subject to various
expression (Toniatti et al., 2004; Goverdhana et al., 2005). The
refinements (Baron et al., 1997; Urlinger et al., 2000; Das et al.,
tetracycline regulatory system (tet-system) developed by
2004). The original transactivator binds only in the absence
Gossen and Bujard (1992) has become a valuable tool for re-
of tetracycline (TetOff), whereas modifications have led to
peated transgene induction. It is based on the incorporation of
the reverse function (Gossen et al., 1995), i.e., the reverse
two components into the same target cell. The first ensures
transactivator binds only in the presence of doxycycline, a
the presence of sufficient amounts of the transactivator, a
tetracycline derivative. This so-called TetOn system has been
fusion protein of the tet-repressor and VP16 proteins from
preferentially used since its invention, particularly in vivo, as
herpes simplex virus, and the second consists of the inducible
it does not require permanent administration of doxycycline
transgene-expressing unit. The latter contains repeats of the
to switch off transgene expression. Furthermore, the transac-
tet-operator sequences (tetO) to which the transactivator can
tivator has been optimized by replacing the original VP16
bind to activate a minimal promoter.
transactivation domain by a so-called minimal domain.
1Experimental Hematology, Hannover Medical School, 30625 Hannover, Germany.
2EUFETS GmbH, 55743 Idar-Oberstein, Germany.
IMPROVED TET-REGULATED ALL-IN-ONE VECTORS
Additionally, the codon usage has been optimized for higher
Ptet-T8 promoter was generated by fusion of the MMTV-U3
expression levels and stability in eukaryotes. One of the most
core promoter fragment (88/þ121) (Loew et al., 2006) to
promising transactivator is the TetOn variant rtTA2s-M2
a tet-operator heptamer with 36-nt center-to-center spaced
(Urlinger et al., 2000), which is used in this study.
operators. Details of the lmg* dual reporter gene, coupling
Effective and stable transfer of the tet-system components
luciferase, and enhanced green fluorescence protein (eGFP)
into a wide range of different cell types can be achieved via
will be published elsewhere (Loew et al., 2010b) and are
viral delivery systems (Kenny et al., 2002; Vigna et al., 2002;
available on request.
Chtarto et al., 2003; Barde et al., 2006; Loew et al., 2006). Thecomponents of the tet-system can be delivered either on
Cultivation of cells
separate vectors (the so-called two-vector system) or in the
HT1080 cells were cultured in Dulbecco's modified Eagle's
more advanced approach by a single vector (the all-in-
medium (Biochrom, Berlin, Germany) supplemented with
one vector system). The major hindrances for the successful
10% fetal calf serum (FCS) (PAA, Pasching, Austria) and
use of the tet-system are reliable introduction of both com-
0.1 mg/ml sodium pyruvate (PAA). BaF3 and 32D cells were
ponents into the same cell and a high regulatory window,
cultivated in RPMI 1640 medium (PAA) supplemented with
i.e., high induction of the transgene and tight regulation in
10% FCS, 0.1 mg/ml sodium pyruvate and 5 ng of mIL-3/ml
the absence of induction. Both approaches, therefore, face
(Peprotech, London, UK). All cells were incubated at 378C and
some problems. The two-vector system often relies on pre-
selection for the integration of the transactivator-expressing
2. For induction of tet-regulated transgene expression,
cells were cultivated in the presence of doxycycline (Sigma)
unit (Gopalkrishnan et al., 1999; Qu et al., 2004). In the next
at 1 mg/ml for 4 days. Medium containing doxycyline was
step, the second vector containing the inducible cassette is
refreshed every 2 days. Transduced cells were sorted ac-
introduced, followed by a second selection to identify clones
cording to eGFP fluorescence in the presence of doxycyline on
displaying tightly regulated transgene expression. The all-in-
a FACSAria (BD Bioscience, Heidelberg, Germany). Cells
one vector system circumvents the need for preselection,
were subsequently cultivated for 12 days in the absence of
because a single transduction is sufficient for introducing all
doxycyline before the background activity was measured.
components needed for tet-regulated transgene expression(Paulus et al., 1996). The major drawback of this system is a
Preparation of viral supernatant, transduction,
typically much higher background activity compared with
the two-vector system. The all-in-one vector approach,therefore, showed regulatory windows of maximum 500-fold,
For preparation of viral supernatant, 293T cells were seeded
even after clonal selection (Kafri et al., 2000; Haack et al., 2004;
onto 10-cm dishes and cotransfected (calcium phosphate)
Barde et al., 2006). Recently, transposon based systems have
with plasmids coding for the viral vector (10 mg/dish), gag/
attracted interest for the stable transfer of expression cassettes
pol (10 mg), and VSV-G (0.5 mg) envelope protein in the pres-
into target cells (Ivics et al., 1997; Wilson et al., 2007; Ma´te´s et al.,
ence of 20 mM HEPES (PAA) and 25 mM chloroquine (Sigma).
2009). So far, however, like for viral one-vector systems, the
Every 12 h, the medium of the transfected producer cells was
tet-regulation suffered from high background activity, even
replaced by 8 ml of fresh culture medium including 20 mM
after clonal selection, after transposon-mediated transfer into
HEPES. The supernatant was harvested 36 h after transfec-
target cells (Saridey et al., 2009).
tion, sterile-filtrated, and stored in aliquots at 808C. Titration
In this study, we describe a novel all-in-one vector system,
of viral supernatants was performed on SC-1 cells in the
allowing tight control of transgene expression without loss
presence of protamine sulfate (Sigma; 4 mg/ml) and doxycy-
of inducibility. The central refinement of our vectors consists
cline (Sigma; 1 mg/ml). Cells (1105) were seeded on six-well
of modifications of the regulatory cassettes, employing new
plates 24 h prior to infection. The transduction was performed
Ptet-promoters. Combined with small alterations of vector
using serial dilutions in 1 ml final volume, and fresh medium
architecture, the modifications improved transgene regula-
including doxycycline was added 24 h after transduction. The
tion in murine and human bulk cell cultures after retroviral
cells were FACS-analyzed 6 days after transduction. The titers
and nonviral gene transfer, which greatly simplifies the ap-
were compared on the basis of transducing units per millili-
plication of tet-regulated expression in basic biology and so-
ter of supernatant (TU/ml). For analyzing the tet-regulated
matic gene therapy.
transgene expression, 1105 HT1080 cells were seeded on 24-well plates 24 h prior to transduction. Supernatants of known
Materials and Methods
titer were added at a multiplicity of infection (MOI) of 0.1 or 3,as described in Results, in the presence of protamine sulfate
and doxycyline. Populations obtained with MOI 0.1 (1–3%
All components needed for tet-regulated transgene ex-
positive cells) were enriched by one round of sorting, whereas
pression were subsequently introduced into plasmids con-
MOI 3 populations were not enriched. For comparison, the
taining either the basic ES.1-g-retroviral backbone (Loew et al.,
luciferase values were normalized to 100% eGFP-positive
2010a) or the terminal repeats for Sleeping Beauty transpo-
sase, kindly provided by Z. Ivics (Ma´te´s et al., 2009). The Ptet-
Cotransfection of HT1080 cells with plasmids for transient
promoter variants Ptet-T2, -T6, and -T11 were generated by
expression of Sleeping Beauty transposase (2 mg of pCMV-
PCR with overlapping oligos by standard procedures as re-
SB100x; Ma´te´s et al., 2009) and the transposable element
commended by the suppliers (Phire-Taq, Biozym, Oldendorf,
(2 mg) was performed using polyethylenimine (PEI; 25 kDa
Germany), respectively. Structure and sequence details are
linear; Polyscience, Niles, IL). Cells were seeded on six-well
given in Supplementary Figs. S1 and S2 (Supplementary Data
plates. One hundred microliters of PEI (0.1 g/L in 150 mM
are available online at www.liebertonline.com/hum). The
NaCl; pH 5.5) reagent and 100 ml of DNA solution (5 mg of
HEINZ ET AL.
DNA in 150 mM NaCl; pH 5.5) were added to 1.8 ml of
MOV-scT2 and MOV-hcT2 (Fig. 1A). Based on the Ptet-1
medium. Transfection reagent was replaced with normal
(Gossen and Bujard, 1992), the minimal promoter Ptet-T2
medium including doxycyline after *12 h.
(Supplementary Fig. S1) was developed, which contains con-sensus sequences for the TATA box (cTATA) and the binding
Reporter gene analysis
site of the transcription factor IIB (cTFIIB) (Lagrange et al.,1998). In the context of the monocistronic vectors, these
eGFP fluorescence was measured with a FACSCalibur (BD
modifications increased the regulatory window by *10-fold,
Bioscience) and analyzed using FlowJo software (Tree Star
due to increased inducible activity and a reduced background
Inc., Ashland, OR). Dead cells were excluded for analysis
activity in the off-state of the system (Loew et al., 2010b).
through exclusion of propidium iodide (Sigma; 1 mg/ml)-
The basic experimental design is shown in Fig. 1B. The
positive cells. Luciferase activity was measured as previously
regulatory characteristics of the vectors were investigated
described (Loew et al., 2010a). In brief, cells were centrifuged
by the expression of the lmg* dual reporter gene, consisting
and resuspended in lysis buffer. Typically 1–10 ml of the cell
of luciferase and eGFP, that allowed the simultaneous mea-
lysate was measured at room temperature on a tube lumin-
surement of both gene activities (Loew et al., 2010b). Human
ometer (LB 9507; Berthold Technologies, Bad Wildbad, Ger-
HT1080 cells were transduced to an efficiency of a maximum
many). Values were normalized against the total protein
20% eGFP-positive cells after induction, and highly purified
content of the cell lysate. Protein determination was per-
populations of transduced cells (>90%) were obtained by
formed using the Coomassie Plus (Bradford) Assay kit (Pierce
FACS. The vector copy number was determined via qPCR
Biotechnology, Rockford, IL). One microliter of cell lysate was
(Table 1), revealing a similar average of vector integrates for
treated according to the manufacturer's instruction in tripli-
all tested populations. After cultivation of these sorted pop-
cate. Analysis was performed on a microplate reader and
ulations in either the presence (i.e., ‘‘on-state'') or absence
analyzed with SoftMax Pro 4.0 software (Molecular Devices,
(‘‘off-state'') of doxycycline, the cells were analyzed for eGFP
Sunnyvale, CA). For a standard curve, different amounts of
fluorescence and luciferase activity.
bovine serum albumin (0.5–8 mg) were used. Statistical anal-ysis was performed using Student's t test.
Exploring effects of vector elements
on the regulatory properties of the MOV vector
Mean copy number was determined via quantitative PCR
We determined the tet-inducible transgene expression of
(qPCR) using primers detecting the wPRE (woodchuck
the vectors MOV-scT2 and MOV-hcT2, in HT1080 cells. The
posttranscriptional element; forward, 50-GAGGAGTTGTGG
dynamic range of gene regulation based on the induced eGFP
CCCGTTGT-30; reverse, 50-TGACAGGTGGTGGCAATGCC-30)
expression and the luciferase activity was similar (*220-fold)
(Modlich et al., 2006) and PTBP2 (polypyrimidine tract bind-
for both constructs (Fig. 1C). Thus, MOV-hcT2 was chosen as
ing protein 2; tm_PTBP2_optimized2_FW: 50-TCTCCA
an initial reference for further experiments. Next, we tested
whether the removal of the splice acceptor from MOV-hcT2
GTTCCCGCAGAATGGTGAGGTG-30) as internal reference
would lead to higher vector titers. For this purpose, we re-
for human and mouse cells (Rahman et al., 2004). qPCR was
moved the pol/env border fragment containing the native
performed using FAST SYBR Green reagent (Stratagene,
splice acceptor (SA) site, resulting in the vector MOV.1-hcT2
Santa Clara, CA) on a StepOnePlus cycler equipped with
(Fig. 1D). As shown in Fig. 2, no significant differences in
StepOne Software v2.0 (Applied Biosystems, Carlsbad, CA).
the retroviral titers were observed, with titers in the range of
For quantification, a plasmid standard was used containing
1–3106 TU/ml. However, comparison of the luciferase ac-
the sequences for wPRE and PTBP2.
tivities determined in the enriched cell populations (Fig. 1D,right panel) revealed a fivefold reduction of background ex-
pression in the off-state in populations transduced by MOV.1-hcT2, whereas the level of induction remained unchanged.
Retroviral ‘‘all-in-one'' vector: design
Thus, the dynamic range of gene regulation was increased
and experimental outline
three- to fourfold (Fig. 1D, left panel) by this modification of
We constructed bidirectional tetracycline-inducible all-in-
the vector backbone.
one vectors, integrating all components required for tet-regulated transgene expression into the ES.1-g-retroviral SIN
Introduction of improved Ptet-promoters
vector backbone (Loew et al., 2010a). The reverse (TetOn)
further reduces background expression
transactivator rtTA2S-M2 (Urlinger et al., 2000) was expressedunder the control of the human phosphoglycerate kinase
To further increase the regulatory window, new Ptet-
promoter (hPGK), which is constitutively active in a wide
promoters, Ptet-T6, Ptet-T8, and Ptet-T11 (Supplementary
range of mammalian cells. The inducible unit was inserted as
Figs. S1 and S2) were integrated into the MOV.1-hcT2
an antisense expression cassette (30–50relative to the viral ge-
backbone, resulting in the vectors MOV.1-hcT6, MOV.
nome), which consisted of an optimized tet-responsive pro-
1-hcT8, and MOV.1-hcT11, respectively (Fig. 1D). The intro-
moter (Ptet-T2) containing a tet-operator heptamer fused to a
duction of the new Ptet-promoters resulted in an improved
minimal promoter followed by the cDNA of choice, a con-
signal-to-noise ratio in transduced HT1080 cell populations,
stitutive transport element from Mason Pfizer Monkey Virus
i.e., the background expression in the off-state was reduced
(CTE) (Schambach et al., 2000) and polyA signals from either
while high induction levels were maintained, clearly dem-
the SV40 (SV40pA) or the human growth hormone (hghpA).
onstrating the advanced regulatory properties of these novel
These initial MoMLV-based bidirectional vectors were termed
Ptet-promoters (Fig. 3A, left panel). Based on the luciferase
IMPROVED TET-REGULATED ALL-IN-ONE VECTORS
Experimental outline and ba-
sic all-in-one vectors. (A) ES.1 based g-retroviral vector with SIN-LTR (DU3),extended packaging region (C/Cþ)and pol/env (p/e) border fragmentincluding the native splice acceptorsite (SA). All components needed fortet-regulated transgene expression wereinserted as a bidirectional expressioncassette. The reverse tet-responsivetransactivator variant M2 is constitu-tively expressed by the human PGKpromoter (þstrand), followed by thewoodchuck
transcriptional regulatory element (PRE).
In the antisense direction (strand), thetet-inducible expression cassette is in-serted along with the constitutivetransport element (CTE), from MasonPfizer Monkey Virus, and either SV40late (SV40pA) or human growth hor-mone (hghpA) polyadenylation signal,resulting in the vectors MOV-scT2 andMOV-hcT2, respectively. Lmg* is a fu-sion protein of luciferase and eGFP. (B)In the basic experimental design,HT1080 cells were infected to obtain aprimary infection rate of <20%, andcells positive for eGFP were sorted toanalyze the regulation, based on eGFPfluorescence and luciferase activity inmass cultures. (C) Left panel: Fluores-cence signals of HT1080 cell populationstransduced by MOV-scT2 (dotted line)or MOV-hcT2 (solid line). Right panel:Luciferase activities determined fromthe identical populations (means SD;n ¼ 3). (D) Schematic outline of the ret-roviral backbone modification. Basedon the vector MOV-hcT2, the pol/envborder fragment containing the nativesplice acceptor site was removed, re-sulting in the vector MOV.1-hcT2. Leftpanel: Representative FACS analysisdetermined for HT1080 populationstransduced by MOV-hcT2 (dotted line)or MOV.1-hcT2 (solid line). Right panel:Luciferase activity of the identical pop-ulations (means SD; n ¼ 3; *P < 0.5).
Introduction of Ptet-T6, Ptet-T8, andPtet-T11 resulted in the vectors MOV.1-hcT6, MOV.1-hcT8, and MOV.1-hcT11,respectively.
measurements, the introduction of Ptet-T6 led to an ap-
activity upon induction was reduced only *1.4- to 1.9-fold
proximately threefold reduction of background activity rel-
when compared with Ptet-T2. Moreover, the introduction of
ative to the Ptet-T2 promoter, whereas induction was only
all modified minimal promoters into the MOV.1 backbone
moderately decreased (*15% decline). The introduction of
resulted in approximately twofold higher vector titers com-
Ptet-T8 and Ptet-T11 promoters (for details, see Materials
pared with the Ptet-T2 variant (Fig. 2). Taken together, the
and Methods) further reduced background expression.
introduction of the novel Ptet-promoters into the bidirec-
Measurement of luciferase revealed an *13- to 35-fold de-
tional viral vector context increased the dynamic range of
crease of background activity in the off-state, whereas the
gene regulation in transduced HT1080 cell populations from
HEINZ ET AL.
Table 1. Comparison of Mean Copy Numbers
and Standard Deviations (SD) of the Sorted
Populations Analyzed in this Study
Comparison of titers. Titers were determined for the
vectors used in this study. Titration was based on eGFPfluorescence and was performed on SC-1 cells. Values aregiven as transducing units per milliliter (TU/ml). Data are
*700-fold for Ptet-T2 up to *2,000-, 7,000-, and 14,000-fold
shown as means SD (n ¼ 3). n.s., data not significantly dif-
for the Ptet-T6, Ptet-T8, and Ptet-T11 promoter, respectively
ferent (P > 0.05); *P < 0.05; **P < 0.01.
(Fig. 3A, right panel), combined with the additional advan-tage of increased vector titers.
vector production. Thus, we assumed that the inversion ofthe regulatory unit, preventing the generation of antisense
Impact of high gene transfer rates
transcripts in packaging cells, might further improve vector
on the tet-induced gene regulation
titers. Indeed, the inversion of the regulatory unit, result-
In many gene therapy trials, multiple transduction cycles
ing in the unidirectional vectors MOV.1-senseT6, MOV.1-
were performed to ensure sufficient gene transfer (30–60%),
senseT8, and MOV.1-senseT11 as illustrated in Fig. 4A, led
potentially resulting in two to four vector copies per cell in
to two- to threefold higher viral titer (*1–2107 TU/ml;
>30% of the transduced cells (Kustikova et al., 2003; Fehse
Fig. 2). However, determination of luciferase activity in
and Roeder, 2008). Thus, we further explored whether the
transduced HT1080 cells (Fig. 4B), revealed a 1.3- to 6-fold
improved regulatory performance of our novel all-in-one
reduced dynamic range of transgene regulation for these
vectors is maintained in cells containing more than one vector
unidirectional vectors when compared with their bidirec-
insertion. We compared the luciferase activity in the on- and
tional counterparts (Fig. 4C). Nevertheless, the unidirec-
off-state between HT1080 cell pools that were transduced at
tional vectors still mediated a 1,000- to 10,000-fold gene
an MOI of either 0.1 or 3. Transduction of HT1080 cells at an
MOI of 3 resulted in gene transfer rates ranging from 47% to69% for the different MOV.1 vectors, whereas at an MOI of 0.1
Properties of the unidirectional retroviral
the gene transfer efficiencies were below 3%. For all three
vectors in murine hematopoietic cell lines
MOV.1 vectors, the range of transgene regulation observed in
To test whether the unidirectional all-in-one vectors ensure
HT1080 cells transduced at an MOI of 3 was only slightly
also a robust high-level transgene regulation in other tissue
lower (1.6- to 2.9-fold) than that in cell pools transduced at an
culture models, we examined their regulatory properties in
MOI of 0.1; thus, the dynamic window of gene regulation was
murine hematopoietic cell lines. BaF3 (a pro B cell line) and
maintained at levels above 1,000-fold (Fig. 3B). Furthermore,
32D cells (a bone marrow-derived myeloid cell line), both
as summarized in Fig. 3C, the improved regulatory window of
widely used for signaling studies, were transduced and en-
our novel all-in-one vectors at high MOIs was also retained in
riched by FACS as described for HT1080 cells. In contrast to
four other established lines derived from a variety of tissues.
the induction levels achieved in HT1080 cells, transgene ex-pression levels in both hematopoietic cell lines were highly
Comparison of bidirectional vs. unidirectional
reduced (four- to 30-fold) in the on-state for both the bidi-
vector architecture
rectional and the unidirectional vectors (Fig. 5A). However,
For gene therapeutic approaches, the vector titers that
unidirectional vectors showed up to sixfold and 16-fold re-
can be achieved for a certain construct are important. Titers
duced background expression in BaF3 and 32D cells, in a side-
generated by transient transfection of packaging cells with
by-side comparison with the bidirectional vectors (Fig. 5A).
the bidirectional vectors MOV.1-hcT6 and MOV.1-hcT8
Overall, the unidirectional vector MOV.1-senseT11 conferred
were about 5–6106 TU/ml. The increased titers after Ptet-
the highest dynamic range of gene regulation (*1,000-fold)
T2 was replaced by Ptet-T6, Ptet-T8, or Ptet-T11 within the
in BaF3 cells, whereas in 32D cells the best regulatory win-
bidirectional MOV.1 vectors (Fig. 2) suggested that the new
dow (2,800-fold) was achieved with the unidirectional vector
Ptet-promoters generated less antisense transcripts during
MOV.1-senseT6 (Fig. 5B).
IMPROVED TET-REGULATED ALL-IN-ONE VECTORS
C 1.0×108
242 1059 787
Novel Ptet-promoters improved the dynamic range of gene regulation after viral transfer. (A) Comparison of the
vectors transferring the novel Ptet promoters. Left panel: Luciferase activities determined in HT1080 cells in the presence andabsence of doxycycline (means SD; n ¼ 3; *P < 0.5; ***P < 0.0001). Right panel: Regulation factors resulting from luciferaseactivity in the on- and off-state. (B) HT1080 cells were transduced with the vectors MOV.1-hcT6, MOV.1-hcT8, and MOV.1-hcT11 at low or high MOI (MOI 0.1 and 3, respectively) and analyzed for their dynamic range. Populations transduced at anMOI of 3 were analyzed without enrichment. Shown are luciferase data (left panel; means SD; n ¼ 3) normalized accordingto their transduction efficiency (%pos) and the resulting fold regulation (right panel). (C) The vectors MOV.1-hcT6, MOV.1-hcT8, and MOV.1-hcT11 were used to transduce different cell lines at an MOI of 3. Luciferase values were normalizedaccording to their transduction efficiency (%pos).
HEINZ ET AL.
we tested the unidirectional all-in-one vector concept in a
transposon-based, nonviral vector system. The two compo-
nents of the tet-system were integrated as distinct expression
tetO7 MP lmg* hPGK M2 PRE
units into the Sleeping Beauty transposable element resulting
in TOV-T6, TOV-T8, and TOV-T11 vectors (Fig. 6A). In con-trast to the viral vectors, the terminal repeats of the transpo-
son do not contain a polyA signal; thus, both units received a
polyA signal (SV40pA for the tet-inducible and HGHpA forthe constitutive expressing cassette). HT1080 cells were co-
transfected with TOV-T6, TOV-T8, and TOV-T11 and an ex-pression plasmid encoding the hyperactive Sleeping Beauty
transposase (SB100x) (Ma´te´s et al., 2009). After stable inte-
B 1.0×107
gration, eGFP-positive cells were enriched by FACS and cul-
tivated as described for the viral approach. Determination of
luciferase activity of TOV-T6, TOV-T8, and TOV-T11 trans-
duced cells revealed similar levels of transgene induction, as
ei 1.0×105
was observed in HT1080 populations transduced by the viral
vector counterparts (Fig. 6B). In comparison with the viral
approach, nonviral gene delivery conferred an even stronger
reduction of luciferase activity in the off-state (Fig. 6B, left
panel). Compared with the viral vectors, the background ac-
[r 1.0×102
tivity was reduced four- and sixfold for Ptet-T6 and Ptet-T8controlled gene expression and, as a consequence, the dy-
namic range of gene regulation increased to 18,000- and
25,000-fold. In contrast to the findings obtained with the viral
vectors in transduced HT1080 cells, the introduction of Ptet-
T11 showed no further improvement compared with Ptet-T8.
In summary, we showed that improved tet-regulated all-
in-one vectors, based on the incorporation of novel minimalpromoters and modification of the vector architecture, re-
sulted in highly improved regulatory windows in hemato-
poietic and nonhematopoietic cell lines. In particular, our
novel all-in-one vectors display very low background ex-
pression in the off-state, which is of major interest for many
approaches in gene therapy and cell biology.
The development of vectors, viral or nonviral, able to
transfer both components of the tet-system simultaneously
into a target cell, has been the subject of many studies. Inter-
estingly, almost all research on this topic was done by col-
leagues engaged in the development of gene therapy, which isa consequence of the work with primary cells that do not
Comparison of bi- and unidirectional vectors in
allow extended ex vivo handling, e.g., preselection. However,
HT1080 cells. (A) Schematic outline of the modification in the
the tight regulation of gene expression in cell popula-
vector architecture. The tet-inducible cassette was inverted
tions transduced by such all-in-one vectors was hampered
within the MOV.1-hc backbone; therefore, expression of both
by the interference of the Ptet-promoters (mostly Ptet-1) and
genes is unidirectional. Resulting vectors were termed MOV
the promoters (e.g., CMVie-promoter) used to express the tet-
.1-senseT6, -senseT8, and -senseT11, respectively. (B) Luci-
transactivators. Therefore, in most all-in-one vectors de-
ferase activity determined in enriched HT1080 cell popula-
scribed so far, the induction of gene expression did not exceed
tions transduced by the indicated vectors. (C) The regulatorywindow based on luciferase activity determined in the on-
100- to 500-fold and displayed relatively low signal-to-noise
and off-state.
ratios, even in single-cell clones (Gopalkrishnan et al., 1999;Johansen et al., 2002; Vigna et al., 2002).
In this study, we described tet-inducible all-in-one vec-
tor systems optimized for tightly regulated transgene ex-
A nonviral approach results in highly reduced
pression in nonclonal cell populations, as required for gene
activity in the uninduced state
therapy approaches. Optimization was achieved by alter-
DNA transposon-mediated gene delivery systems have
ations of the retroviral architecture and incorporation
recently been developed as an alternative tool for retroviral
of novel tet-responsive promoters, together leading to
gene transfer because they offer important advantages
improved regulatory windows greater than 10,000-fold in
over viral vectors (VandenDriessche et al., 2009). Therefore,
nonclonal cell populations. Remarkably, we were able to
IMPROVED TET-REGULATED ALL-IN-ONE VECTORS
further improve the regulatory performance two- to eight-
fold by incorporation of distinct expression cassettes for the
tet-dependent transactivator and the regulatory unit into a
Sleeping Beauty transposable element, resulting in up to
The tet-responsive promoters Ptet-T6, Ptet-T8, and Ptet-
T11 (Supplementary Figs. S1 and S2), introduced into the all-
in-one vector systems, displayed reduced backgroundexpression in the off-state of transduced cell populations
when compared with Ptet-T2, a tet-responsive promoterclosely related to Ptet-1 (Gossen and Bujard, 1992). The
mg protein]
structure and functional properties of Ptet-T2 and Ptet-T6
promoters have been described in detail in a recent study
(Loew et al., 2010b). The background expression as well
as the induction level of Ptet-T8 was reduced comparedwith those of Ptet-T6, thus confirming earlier results with
this minimal promoter (Loew et al., 2006). Interestingly, the
MMTV-core promoter, as designed by evolution, contains
several cis-elements that were assumed to be involved in its
native regulation of hormone-responsive activity. In addition
senseT6 se
to one GRE (glucocorticoid-receptor element), NF-1 and Oct-1 (Fox-AI) binding sites especially were of importance. Their
coordinate binding is proposed to be responsible for nucle-
osome repositioning during activation of transcription by the
steroid hormone (Belikov et al., 2004; Holmqvist et al., 2005).
Thus, the tightly controlled expression of Ptet-T8 may be
related to a particular promoter structure during the off-state
of tet-controlled gene expression. This finding prompted usto modify the Ptet-T6 promoter accordingly. All residual
CMVie-promoter sequences (50/–36 and 23/þ16) in-cluding the initiator element (Inr) were replaced by MMTV
sequences. The resulting promoter, Ptet-T11, indeed showed
mg protein]
superior background control in HT1080 cell populations (Fig.
3). However, further experiments to investigate whether re-
moval of the Inr element and/or the introduction of the Oct-
1 (Fox-AI) binding site contributed to the enhanced control ofbackground expression in the off-state, when transferred by
otherwise identical viral vectors, were beyond the scope of
this study. Importantly, the regulatory properties of the
vectors were fairly maintained even at high MOI, a test done
to mimic the situation in gene therapy trials (Kustikova et al.,
senseT6 se
2003; Fehse and Roeder, 2008). Similar investigations for the
performance of one-vector systems so far have been rarely
included in publications (Barde et al., 2006).
The transiently produced vector titers differed significantly
depending on the Ptet-promoter and vector architecture.
Increased titers were observed for bidirectional vectors, trans-
ferring Ptet-promoters displaying tightly controlled back-ground expression in the off-state. The decreased backgroundactivity may generate less antisense transcripts, able to interfere
Regulated gene expression in hematopoietic cell
lines. (A) The vectors MOV.1-hcT6, MOV.1-senseT6, MOV.1-senseT8, MOV.1-hcT11, and MOV.1-senseT11 were used totransduce the hematopoietic cell lines BaF3 (upper panel) and
32D (lower panel). Luciferase activity was determined from
enriched cell populations (means SD; n ¼ 3; *P < 0.5;
**P < 0.01; ***P < 0.0001). (B) The regulatory window based
on luciferase activity determined in the on- and off-state.
HEINZ ET AL.
transposable element
tio 20000
mg protein]
Tet-inducible Sleeping Beauty transposase system. (A) Schematic outline of the transposable element containing all
components needed for tet-regulated transgene expression. The distinct tet-inducible and the constitutive transactivatorexpression cassettes were introduced for unidirectional expression, flanked by the terminal repeats (ITR) of Sleeping Beautytransposon. (B) Luciferase activity (left panel; means SD; n ¼ 3) and background activity for all vectors determined afterenrichment of stably transformed HT1080 cell populations. The regulatory window for these vectors is shown (right panel).
with homodimer formation of the viral genome during viral
Recently, transposon-based vector systems were used for
particle formation and/or eliciting a cellular response against
the delivery of expression cassettes (Ivics et al., 1997; Ding et al.,
double-stranded RNA (Maetzig et al., 2009). The same mech-
2005; Ma´te´s et al., 2009). Using the tet-system in the context of
anism would also explain the approximately threefold increase
a transposon based DNA vector, only low regulatory win-
of titers obtained with the unidirectional vectors.
dows have been reported (Saridey et al., 2009). We assumed
Interestingly, although in HT1080 cell populations the bi-
that the novel Ptet-promoters should also mediate tightly
directional design of the viral vectors resulted in a higher
controlled gene expression in a transposon-based approach.
dynamic range compared with the unidirectional expression
Indeed, nonclonal HT1080 cultures stably transformed by
system, the latter was superior in hematopoietic cell lines.
Sleeping Beauty displayed very low background activity in
This cell type-dependent shift of the dynamic range of tet-
the off-state, resulting in an outstanding high regulation of
regulation toward lower activity might be explained by dif-
gene expression (>25,000-fold) in bulk cultures. The presence
ferent compositions of the basal transcription machinery in
or absence of viral components, e.g., the pol/env region (Fig.
these cells, as demonstrated for myoblast and terminally
1D), or the altered integration preferences offer possible ex-
differentiated myotubes (Deato and Tjian, 2007). The indi-
planations. Preferential integrations of the g-retroviral vectors
vidual composition of the transcription machineries may
in the vicinity of transcriptional start sites or CpG islands
also explain preferences for regulatory units observed in
might lead to stronger interactions of the minimal promoter
standard cell lines, e.g., NIH3T3, CHO, HeLa, or 293T, after
with nearby cellular enhancers (Lewinski et al., 2006; Beard
introduction of Ptet-promoters by viral vectors (Fig. 3C).
et al., 2007). Accordingly, the more random integration of
Other studies have also found different regulatory windows
Sleeping Beauty transposon throughout the genome (Yant
in different cell types, affecting both inducibility and back-
et al., 2005) should reduce interference with cellular enhancers,
ground activity (Haack et al., 2004; Markusic et al., 2005).
resulting in lower background activity of the minimal pro-
Overall, we concluded that a strong interdependence be-
moter in the off-state. Studies using clonal analysis clearly
tween the vector architecture, the Ptet-promoters, and the
showed that different clones behave differently in terms of
cell type exists, underlining the need to optimize the setting
their regulation, indicating an influence of the integration site
for specific applications.
on regulatory behavior (Saridey et al., 2009). However, the
IMPROVED TET-REGULATED ALL-IN-ONE VECTORS
examination of basic mechanisms involved in chromosomal
Tetracycline-inducible transgene expression mediated by a
interference with the Ptet-promoters was beyond the scope of
single AAV vector. Gene Ther. 10, 84–94.
this study, which aimed to provide suitable transfer vectors
Das, A.T., Zhou, X., Vink, M., Klaver, B., Verhoef, K., Marzio, G.,
for regulated gene expression in bulk cultures.
and Berkhout, B. (2004). Viral evolution as a tool to improve the
Together, the new vectors described here will likely im-
tetracycline-regulated gene expression system. J. Biol. Chem.
prove the utility of the TetOn system in gene therapy ap-
279, 18776–18782.
proaches. The regulatory properties of the Ptet-promoters
Deato, M.D., and Tjian, R. (2007). Switching of the core tran-
were target cell-specific, affected by the vector architecture
scription machinery during myogenesis. Genes Dev. 21, 2137–
and greatly improved when a transposon-based transfer sys-
tem was used. Because all data were obtained on cell popu-
Ding, S., Wu, X., Li, G., Han, M., Zhuang, Y., and Xu, T. (2005).
Efficient transposition of the piggyBac (PB) transposon in
lations, misleading results that might arise from influences of
mammalian cells and mice. Cell 122, 473–483.
the chromosomal context in clonal analysis were avoided.
Fehse, B., and Roeder, I. (2008). Insertional mutagenesis and
clonal dominance: biological and statistical considerations.
Gene Ther. 15, 143–153.
This work was supported by grants of the German min-
Gopalkrishnan, R.V., Christiansen, K.A., Goldstein, N.I.,
istry for Research and Education (CB-Hermes, 01GN0930),
Depinho, R.A., and Fisher, P.B. (1999). Use of the human EF-
the Deutsche Forschungsgemeinschaft (KL 1311/4-1 and
1alpha promoter for expression can significantly increase suc-
Cluster of Excellence REBIRTH Exc 62/1), and the European
cess in establishing stable cell lines with consistent expression: a
Union (PERSIST, HEALTH-F5-2009-222878). The Sleeping
study using the tetracycline-inducible system in human cancercells. Nucleic Acids Res. 27, 4775–4782.
Beauty Transposase System was kindly provided by Zoltan
Gossen, M., and Bujard, H. (1992). Tight control of gene ex-
Ivics, Zsuzsanna Izsva´k, and Lajos Ma´te´s (MDC Berlin). We
pression in mammalian cells by tetracycline-responsive pro-
would like to acknowledge the assistance of the Cell Sorting
moters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547–5551.
Core Facility of the Hannover Medical School supported in
Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W.,
part by Braukmann-Wittenberg-Herz-Stiftung and Deutsche
and Bujard, H. (1995). Transcriptional activation by tetracy-
Forschungsgemeinschaft. The authors thank Tamaryin
clines in mammalian cells. Science 268, 1766–1769.
Godinho for critical reading of the manuscript.
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J.M., Barcia, C.,
Curtin, J.F., Soffer, E.B., Mondkar, S., King, G.D., Hu, J.,
Author Disclosure Statement
Sciascia, S.A., Candolfi, M., Greengold, D.S., Lowenstein, P.R.,
A competing financial interest exists: A patent application
and Castro, M.G. (2005). Regulatable gene expression systemsfor gene therapy applications: progress and future challenges.
for the novel Ptet promoters has been filed by Rainer Loew
Mol. Ther. 12, 189–211.
and Herrmann Bujard.
Haack, K., Cockrell, A.S., Ma, H., Israeli, D., Ho, S.N., McCown,
T.J., and Kafri, T. (2004). Transactivator and structurally op-
timized inducible lentiviral vectors. Mol. Ther. 10, 585–596.
Agha-Mohammadi, S., O'Malley, M., Etemad, A., Wang, Z., Xiao,
Holmqvist, P.H., Belikov, S., Zaret, K.S., and Wrange, O. (2005).
X., and Lotze, M.T. (2004). Second-generation tetracycline-
FoxA1 binding to the MMTV LTR modulates chromatin
regulatable promoter: repositioned tet operator elements opti-
structure and transcription. Exp. Cell Res. 304, 593–603.
mize transactivator synergy while shorter minimal promoter
Ivics, Z., Hackett, P.B., Plasterk, R.H., and Izsvak, Z. (1997).
offers tight basal leakiness. J. Gene Med. 6, 817–828.
Molecular reconstruction of Sleeping Beauty, a Tc1-like trans-
Barde, I., Zanta-Boussif, M.A., Paisant, S., Leboeuf, M., Rameau,
poson from fish, and its transposition in human cells. Cell 91,
P., Delenda, C., and Danos, O. (2006). Efficient control of gene
expression in the hematopoietic system using a single Tet-on
Johansen, J., Rosenblad, C., Andsberg, K., Moller, A., Lundberg,
inducible lentiviral vector. Mol. Ther. 13, 382–390.
C., Bjorlund, A., and Johansen, T.E. (2002). Evaluation of Tet-
Baron, U., Gossen, M., and Bujard, H. (1997). Tetracycline-
on system to avoid transgene down-regulation in ex vivo gene
controlled transcription in eukaryotes: novel transactivators
transfer to the CNS. Gene Ther. 9, 1291–1301.
with graded transactivation potential. Nucleic Acids Res. 25,
Kafri, T., Van Praag, H., Gage, F.H., and Verma, I.M. (2000).
Lentiviral vectors: regulated gene expression. Mol. Ther. 1,
Baum, C., Schambach, A., Bohne, J., and Galla, M. (2006). Ret-
rovirus vectors: toward the plentivirus? Mol. Ther. 13, 1050–
Kenny, P.A., Enver, T., and Ashworth, A. (2002). Retroviral
vectors for establishing tetracycline-regulated gene expression
Beard, B.C., Keyser, K.A., Trobridge, G.D., Peterson, L.J., Miller,
in an otherwise recalcitrant cell line. BMC Mol. Biol. 3, 13.
D.G., Jacobs, M., Kaul, R., and Kiem, H.P. (2007). Unique in-
Kustikova, O.S., Wahlers, A., Kuhlcke, K., Stahle, B., Zander,
tegration profiles in a canine model of long-term repopulating
A.R., Baum, C., and Fehse, B. (2003). Dose finding with ret-
cells transduced with gammaretrovirus, lentivirus, or foamy
roviral vectors: correlation of retroviral vector copy numbers
virus. Hum. Gene Ther. 18, 423–434.
in single cells with gene transfer efficiency in a cell population.
Belikov, S., Holmqvist, P.H., Astrand, C., and Wrange, O. (2004).
Blood 102, 3934–3937.
Nuclear factor 1 and octamer transcription factor 1 binding
Lagrange, T., Kapanidis, A.N., Tang, H., Reinberg, D., and Eb-
preset the chromatin structure of the mouse mammary tumor
right, R.H. (1998). New core promoter element in RNA poly-
virus promoter for hormone induction. J. Biol. Chem. 279,
merase II-dependent transcription: sequence-specific DNA
binding by transcription factor IIB. Genes Dev. 12, 34–44.
Chtarto, A., Bender, H.U., Hanemann, C.O., Kemp, T., Lehtonen,
Lewinski, M.K., Yamashita, M., Emerman, M., Ciuffi, A.,
E., Levivier, M., Brotchi, J., Velu, T., and Tenenbaum, L. (2003).
Marshall, H., Crawford, G., Collins, F., Shinn, P., Leipzig, J.,
HEINZ ET AL.
Hannenhalli, S., Berry, C.C., Ecker, J.R., and Bushman, F.D.
Saridey, S.K., Liu, L., Doherty, J.E., Kaja, A., Galvan, D.L.,
(2006). Retroviral DNA integration: viral and cellular deter-
Fletcher, B.S., and Wilson, M.H. (2009). PiggyBac transposon-
minants of target-site selection. PLoS Pathog. 2, e60.
based inducible gene expression in vivo after somatic cell gene
Loew, R., Vigna, E., Lindemann, D., Naldini, L., and Bujard, H.
transfer. Mol. Ther. 17, 2115–2120.
(2006). Retroviral vectors containing Tet-controlled bidirec-
Schambach, A., Wodrich, H., Hildinger, M., Bohne, J., Krausslich,
tional transcription units for simultaneous regulation of two
H.G., and Baum, C. (2000). Context dependence of different
gene activities. J. Mol. Genet. Med. 2, 107–118.
modules for posttranscriptional enhancement of gene expres-
Loew, R., Meyer, Y., Kuehlcke, K., Gama-Norton, L., Wirth, D.,
sion from retroviral vectors. Mol. Ther. 2, 435–445.
Hauser, H., Stein, S., Grez, M., Thornhill, S., Thrasher, A.,
Toniatti, C., Bujard, H., Cortese, R., and Ciliberto, G. (2004).
Baum, C., and Schambach, A. (2010a). A new PG13-based
Gene therapy progress and prospects: transcription regulatory
packaging cell line for stable production of clinical-grade self-
systems. Gene Ther. 11, 649–657.
inactivating gamma-retroviral vectors using targeted integra-
Urlinger, S., Baron, U., Thellmann, M., Hasan, M.T., Bujard, H.,
tion. Gene Ther. 17, 272–280.
and Hillen, W. (2000). Exploring the sequence space for
Loew, R., Heinz, N., Hampf, M., Bujard, H., and Gossen, M.
tetracycline-dependent transcriptional activators: novel mu-
(2010b). Improved Tet-responsive promoters with minimized
tations yield expanded range and sensitivity. Proc. Natl. Acad.
background expression. BMC Biotechnol. 10, 81 (November
Sci. U.S.A. 97, 7963–7968.
VandenDriessche, T., Ivics, Z., Izsva´k, Z., and Chuah, M.K. (2009).
Maetzig, T., Galla, M., Brugman, M.H., Loew, R., Baum, C., and
Emerging potential of transposons for gene therapy and gen-
Schambach, A. (2010). Mechanisms controlling titer and
eration of induced pluripotent stem cells. Blood 114, 1461–1468.
expression of bidirectional lentiviral and gammaretroviral
Vigna, E., Cavalieri, S., Ailles, L., Geuna, M., Loew, R., Bujard,
vectors. Gene Ther. 17, 400–411.
H., and Naldini, L. (2002). Robust and efficient regulation of
Markusic, D., Oude-Elferink, R., Das, A.T., Berkhout, B., and
transgene expression in vivo by improved tetracycline-
Seppen, J. (2005). Comparison of single regulated lentiviral
dependent lentiviral vectors. Mol. Ther. 5, 252–261.
vectors with rtTA expression driven by an autoregulatory
Wilson, M.H., Coates, C.J., and George, A.L., Jr. (2007). PiggyBac
loop or a constitutive promoter. Nucleic Acids Res. 33, e63.
transposon-mediated gene transfer in human cells. Mol. Ther.
Ma´te´s, L., Chuah, M.K., Belay, E., Jerchow, B., Manoj, N., Acosta-
15, 139–145.
Sanchez, A., Grzela, D.P., Schmitt, A., Becker, K., Matrai, J., Ma,
Yant, S.R., Wu, X., Huang, Y., Garrison, B., Burgess, S.M., and Kay,
L., Samara-Kuko, E., Gysemans, C., Pryputniewicz, D., Miskey,
M.A. (2005). High-resolution genome-wide mapping of trans-
C., Fletcher, B., VandenDriessche, T., Ivics, Z., and Izsva´k, Z.
poson integration in mammals. Mol. Cell. Biol. 25, 2085–2094.
(2009). Molecular evolution of a novel hyperactive SleepingBeauty transposase enables robust stable gene transfer in ver-tebrates. Nat. Genet. 41, 753–761.
Address correspondence to:
Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knoess, S.,
Dr. Bernhard Schiedlmeier
Schambach, A., and Baum, C. (2006). Cell-culture assays re-
Experimental Hematology
veal the importance of retroviral vector design for insertional
Hannover Medical School
mutagenesis. Blood 108, 2545–2553.
Carl-Neuberg-Straße 1
Paulus, W., Baur, I., Boyce, F.M., Breakefield, X.O., and Reeves,
30625 Hannover, Germany
S.A. (1996). Self-contained, tetracycline-regulated retroviral
vector system for gene delivery to mammalian cells. J. Virol.
70, 62–67.
Qu, Z., Thottassery, J.V., Van Ginkel, S., Manuvakhova, M.,
Westbrook, L., Roland-Lazenby, C., Hays, S., and Kern, F.G.
(2004). Homogeneity and long-term stability of tetracycline-
55743 Idar-Oberstein, Germany
regulated gene expression with low basal activity by using thertTA2S-M2 transactivator and insulator-flanked reporter vec-
tors. Gene 327, 61–73.
Rahman, L., Bliskovski, V., Kaye, J.K., and Zajac-Kaye, M.
Received for publication May 14, 2010;
(2004). Evolutionary conservation of a 2-kb intronic sequence
accepted after revision September 3, 2010.
flanking a tissue-specific alternative exon in the PTBP2 gene.
Genomics 83, 76–84.
Published online: December 7, 2010.
Source: http://ozyme.fr/gammes/clo/pdf/clo_tet-one_publi_heinz.pdf
where can i find support and information? PSC Partners Seeking a Cure is a 501(c)3 nonprofit foundation that endeavors to find a cure for primary sclerosing cholangitis. for more information, or to help fund the cure: Please consider joining our mailing list at: Visit our website at: www.pscpartners.org An online PSC support group was established in 1998. This is a message board (forum) on Yahoo/Health, where PSC patients
Generic Entry, Pay-for-Delay Settlements, and the Distribution of Surplus in the US Pharmaceutical Ruben Jacobo-Rubio∗ John L. Turner† Jonathan W. Williams‡ Using an event study approach, and unique data on Paragraph (iv) pharmaceuticalpatent litigation decisions, we estimate that brand firms value deterrence at $4.6 bil-lion on average while generic entrants value the right to enter, on average, at $236.8million. These estimates account for probabilistic district court decisions and an ap-pellate process. In 2002, the Schering-Plough vs. FTC decision led to a surge in"pay-for-delay" settlements. We estimate that surpluses at stake in decided cases are73% lower after this decision, reducing the direct (per-case) consumer surplus gainsanticipated by the 1984 Hatch-Waxman Act's procedures for early generic entry.